Abstract
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V2 receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ghali, J. K. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology 111, 147–157 (2008).
Chen, S. et al. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nature Clin. Pract. Nephrol. 3, 82–95 (2007).
Ali, F. et al. Therapeutic potential of vasopressin receptor antagonists. Drugs 67, 847–858 (2007).
Yamamura, Y. et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287, 860–867 (1998).
Kondo, K. et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg. Med. Chem. 7, 1743–1754 (1999).
Miyazaki, T. et al.Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 146, 3037–3043 (2005).
Food and Drug Administration. FDA labelling information. FDA web site [online], (2009).
Schrier, R. W. et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355, 2099–2112 (2006).
Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319–1331 (2007).
Ali, F. et al. Conivaptan: a dual vasopressin receptor V1A/V2 antagonist. Cardiovascular Drug Rev. 25, 261–279 (2007).
Udelson, J. E. et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function inpatient with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 49, 2151–2159 (2007).
IMS MIDAS MAT Q4 (IMS Health, 2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J.K.G. is a consultant for Astellas and Otsuka, and has received research grants from CardioKine Inc. and Biogen Idec.
Rights and permissions
About this article
Cite this article
Ghali, J., Hamad, B., Yasothan, U. et al. Tolvaptan. Nat Rev Drug Discov 8, 611–612 (2009). https://doi.org/10.1038/nrd2946
Issue Date:
DOI: https://doi.org/10.1038/nrd2946
This article is cited by
-
Liquid chromatography–tandem mass spectrometry method for determining tolvaptan and its nine metabolites in rat serum: application to a pharmacokinetic study
Archives of Pharmacal Research (2014)
-
The disconnect between phase II and phase III trials of drugs for heart failure
Nature Reviews Cardiology (2013)
-
The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice
Clinical and Experimental Nephrology (2012)
-
Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
Cardiovascular Drugs and Therapy (2011)